NeuroDerm CEO to Present at Upcoming Investor Conferences
Get Alerts NDRM Hot Sheet
Join SI Premium – FREE
REHOVOT, Israel, Feb. 27, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq: NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that CEO Oded S. Lieberman, PhD will present at the following investor conferences:
- Cowen and Company 37th Annual Health Care Conference taking place in Boston, Massachusetts from March 6 – 8, 2017. Dr. Lieberman’s presentation will take place on Monday, March 6 at 2:00pm ET.
- 29th Annual ROTH Conference taking place in Dana Point, California from March 12 – 15, 2017. Dr. Lieberman’s presentation will take place on Tuesday, March 14 at 9:00am PT, 12:00pm ET.
To access the live webcast of the presentation, please visit ir.neuroderm.com/. A replay will be available for a limited time following the presentation.
About NeuroDermNeuroDerm is a clinical-stage pharmaceutical company developing central nervous system (CNS) product candidates that are designed to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration. NeuroDerm is headquartered in the Rabin Science Park, Rehovot, Israel.
NeuroDerm Contact:Oded S. Lieberman, PhD, CEO[email protected]Tel.: +972-8-946 2729; Cell: +1-617-517 6077
U.S. Investor Contact:David CareyLazar Partners Ltd.[email protected]+212-867-1768
Source: NeuroDerm Ltd.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Griffon Corporation Announces Closing of Senior Notes Offering and Amended Credit Facility
- High Profile Cannabis Opens Second Kentucky Dispensary in Wilder, Bringing Medical Access to Northern Kentucky
- ECC Ventures 5 Corp. Enters Into Business Combination Agreement with Bayrock Resources for Qualifying Transaction
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share